A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL) (ZUMA-2) - ZUMA-2

Kite Pharma Inc.0 个研究点目标入组 70 人开始时间: 2017年9月18日最近更新: 2017年10月2日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Kite Pharma Inc.
入组人数: 70

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•101. Pathologically confirmed MCL, with documentation of either overexpression of cyclin D1 or presence of t(11;14)
•102. Up to 5 prior regimens for MCL. Prior therapy must have included:
•- Anthracycline or bendamustine-containing chemotherapy and
•- Anti-CD20 monoclonal antibody therapy and
•- Ibrutinib
•103. Relapsed or refractory disease, as defined by the following:
•- Disease progression after last regimen, or
•- Failure to achieve a PR or CR to the last regimen
•104. At least 1 measurable lesion according to the revised IWG Response Criteria for Malignant Lymphoma (Cheson 2007). Lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy. If the only measurable disease is lymph node disease, at least one lymph node should be = 2 cm
•105. MRI of the brain showing no evidence of CNS lymphoma
•106. At least 2 weeks or 5 half-lives, whichever is shorter, must have elapsed since any prior systemic therapy at the time the subject is planned for leukapheresis, except for systemic inhibitory/stimulatory immune checkpoint therapy. At least 3 half-lives must have elapsed from any prior systemic inhibitory/stimulatory immune checkpoint molecule therapy at the time the subject is planned for leukapheresis (e.g. ipilimumab, nivolumab, pembrolizumab, atezolizumab, OX40 agonists, 4-1BB agonists etc).
•107. Toxicities due to prior therapy must be stable and recovered to = Grade 1 (except for clinically non-significant toxicities such as alopecia)
•108. Age 18 years or older
•109. Eastern cooperative oncology group (ECOG) performance status of 0 or 1
•110. ANC = 1000/uL
•111. Platelet count = 75,000/uL
•112. Absolute lymphocyte count = 100/ uL
•113. Adequate renal, hepatic, pulmonary and cardiac function defined as:
•- Creatinine clearance (as estimated by Cockcroft Gault) = 60 cc/min
•- Serum ALT/AST = 2.5 ULN
•- Total bilirubin = 1.5 mg/dl, except in subjects with Gilbert’s syndrome
•- Cardiac ejection fraction = 50%, no evidence of pericardial effusion as determined by an ECHO, and no clinically significant ECG findings
•- No clinical significant pleural effusion
•- Baseline oxygen saturation > 92% on room air
•114. Females of childbearing potential must have a negative serum or urine pregnancy test. Females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 70
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

排除标准

•201. History of malignancy other than nonmelanomatous skin cancer or carcinoma in situ (e.g. cervix, bladder, breast) unless disease free for at least 3 years.
•202. Autologous stem cell transplant within 6 weeks of planned KTE-C19 infusion.
•203. History of allogeneic stem cell transplantation.
•204. Prior CD19 targeted therapy with the exception of subjects who received KTE-C19 in this study and are eligible for re-treatment.
•205. Prior chimeric antigen receptor therapy or other genetically modified T cell therapy
•206. History of severe, immediate hypersensitivity reaction attributed to aminoglycosides
•207. Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management. Simple UTI and uncomplicated bacterial pharyngitis are permitted if responding to active treatment and after consultation with the Kite Medical Monitor.
•208. Known history of infection with HIV or hepatitis B (HBsAg positive) or hepatitis C virus (anti-HCV positive). A history of treated hepatitis B or hepatitis C is permitted if the viral load is undetectable per quantitative PCR and/or nucleic acid testing.
•209. Presence of any indwelling line or drain (e.g. percutaneous nephrostomy tube, indwelling Foley catheter, biliary drain, or pleural/peritoneal/pericardial catheter). Ommaya reservoirs and dedicated central venous access catheters such as a Port-a-Cath or Hickman catheter are permitted
•210. Subjects with detectable cerebrospinal fluid malignant cells, or brain metastases, or with a history of CNS lymphoma, cerebrospinal fluid malignant cells or brain metastases
•211. History or presence of CNS disorder, such as seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement
•212. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment
•213. Subjects with cardiac atrial or cardiac ventricular lymphoma involvement
•214. History of symptomatic deep vein thrombosis or pulmonary embolism within the last 6 months of enrollment
•215. Requirement for urgent therapy due to tumor mass effects e.g. bowel obstruction or blood vessel compression
•216. Primary immunodeficiency
•217. Any medical condition likely to interfere with assessment of safety or efficacy of study treatment
•218. History of severe immediate hypersensitivity reaction to any of the agents used in this study
•219. Live vaccine = 6 weeks prior to planned start of conditioning regimen
•220. Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant
•221. Subjects of both genders who are not willing to practice birth control from the time of consent through 6 months after the completion of KTE-C19
•222. In the investigators judgment, the subject is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation.
•223. History of autoimmune disease (e.g. Crohns, rheumatoid arthritis, systemic lupus) requiring systemic immunosuppression and/or systemic disease modifying agents within the last 2 years

研究者

发起方

Kite Pharma Inc.

相似试验

进行中（未招募）

1 期

Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) (ZUMA-2)

CTIS2023-506641-35-00Kite Pharma Inc.183

进行中（未招募）

1 期

A Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)Relapsed/Refractory Mantle Cell Lymphoma (MCL)MedDRA version: 20.0Level: PTClassification code 10061275Term: Mantle cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10026801Term: Mantle cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2015-005008-27-ESKite Pharma, Inc.220

进行中（未招募）

1 期

A study evaluating the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Subjects with High-Risk Large B-Cell LymphomaAdult subjects with high-risk large B-cell lymphoma, including either high-grade B-cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 translocations (double-hit or triple-hit lymphomas) or International Prognostic Index (IPI) score =3.MedDRA version: 20.0Level: HLTClassification code 10012819Term: Diffuse large B-cell lymphomasSystem Organ Class: 100000004851

EUCTR2019-002291-13-FRKite Pharma, Inc40

进行中（未招募）

1 期

EUCTR2015-005008-27-NLKite Pharma, Inc.220

招募中

2 期

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)Mantle Cell Lymphoma (MCL)cancer of white blood cells10025322

NL-OMON54549Kite Pharma Inc.20